Basic Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2020; 26(23): 3236-3248
Published online Jun 21, 2020. doi: 10.3748/wjg.v26.i23.3236
Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients
Ute Warnecke-Eberz, Patrick Plum, Viola Schweinsberg, Uta Drebber, Christiane J Bruns, Dolores T Müller, Arnulf H Hölscher, Elfriede Bollschweiler
Ute Warnecke-Eberz, Patrick Plum, Christiane J Bruns, Dolores T Müller, Elfriede Bollschweiler, Department of General, Visceral and Cancer Surgery, University Hospital of Cologne, Cologne 50937, Germany
Viola Schweinsberg, Department of Dermatology, University Hospital of Cologne, Cologne 50937, Germany
Uta Drebber, Institute of Pathology, University Hospital of Cologne, Cologne 50937, Germany
Arnulf H Hölscher, Agaplesion Markus Hospital, Frankfurt 60431, Germany
Author contributions: Warnecke-Eberz U, Bollschweiler E designed the study; Warnecke-Eberz U, Hölscher AH coordinated the study; Schweinsberg V performed the experiments; Warnecke-Eberz U, Bollschweiler E acquired, analysed and interpreted the data; Drebber U did the pathological evaluation and scoring of protein staining; Warnecke-Eberz U, Bollschweiler E, Plum P wrote the manuscript; Müller DT supported writing of manuscript; Bruns CJ supported data interpretation.
Institutional review board statement: The use of human tissue samples and clinical data was approved by the ethics commitee of the University Hospital of Cologne (Germany), all patients provided signed informed consent, and the research was carried out in accordance with the Helsinki Declaration.
Conflict-of-interest statement: The authors disclose any conflicts of interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ute Warnecke-Eberz, PhD, Professor, Department of General, Visceral and Cancer Surgery, University Hospital of Cologne, Kerpener Str. 62, Cologne 50937, Germany. ute.warnecke-eberz@uk-koeln.de
Received: December 30, 2019
Peer-review started: December 30, 2019
First decision: January 19, 2020
Revised: April 20, 2020
Accepted: May 30, 2020
Article in press: May 30, 2020
Published online: June 21, 2020
Core Tip

Core tip: Podoplanin is an oncofetal membrane protein, re-expressed in squamous cell carcinoma of the esophagus. Podoplanin expression seems to be, among others, controlled by miR-363. Chemoradiation results in reduction of podoplanin protein expression, and furthermore, podoplanin is a prognostic factor for survival. This implicates that a decrease of podoplanin might become a therapeutic option.